BSD said that the clinical study data will be presented by Rudiger Wessalowski, associate professor at the Clinic of Pediatric Hematology and Oncology, Heinrich-Heine University, Dusseldorf, Germany, at
Amira has successfully completed Phase 1 studies on its lead DP2 receptor antagonist, AM211, and anticipates that this compound will be developed for the treatment of respiratory diseases
The issued patent covers Mystic’s unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability, reduce the
MMR said that these antibody assets may be used in the development of future treatment options for various autoimmune and B-Cell mediated diseases, which could include lupus nephritis,
The issued patent covers Mystic Pharmaceuticals’ proprietary unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability,
The collaboration is a part of IAVI’s Innovation Fund, a program launched to support the application of novel and unconventional technologies to AIDS vaccine design and development. The
Simultaneously, Actelion Pharmaceuticals has launched Prospect registry, a multicenter, observational, US-based registry that will provide additional clinical experience on patients being treated with Epoprostenol for Injection. Epoprostenol for
Xerecept is an investigational new drug that may present an alternative to dexamethasone for patients with primary and metastatic brain tumors. Xerecept has shown in Phase II and
Vical has reported that TransVax cytomegalovirus (CMV) vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo TransVax is a bivalent DNA vaccine containing
The acquisition provides Abbott with a biologic intended to treat multiple sclerosis (MS) and compounds that complement its existing diverse oncology program. The new Abbott compounds include daclizumab,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.